Bortezomib is effective in primary plasma cell leukemia

被引：28

作者：

Finnegan, Damian P. J.

Kettle, Paul

Drake, Mary

Matthews, Christine

Alexander, H. Denis

Popat, Rakesh

Cavanagh, Jamie D.

Wachsman, William

Morris, T. C. M.

机构：

[1] Belfast City Hosp, Dept Haematol, Belfast BT9 7AD, Antrim, North Ireland

[2] St Bartholomews Hosp, Dept Haematol, London, England

[3] VA San Diego Healthcare Syst, Med & Res Serv, San Diego, CA USA

[4] Univ Calif San Diego, Sch Med, Div Hematol Oncol, San Diego, CA 92103 USA

[5] Univ Calif San Diego, Sch Med, Rebecca & John Moores Canc Ctr, San Diego, CA 92103 USA

来源：

LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 08期

关键词：

D O I：

10.1080/10428190500520954

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：1670 / 1673

页数：4

共 15 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2]

Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia [J].

Bladé, J ;

Kyle, RA .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) :1259-+

[3]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[4]

Bradwell AR, 2001, CLIN CHEM, V47, P673

[5]

Bortezomib is an efficient agent in plasma cell leukemias [J].

Esparís-Ogando, A ;

Alegre, A ;

Aguado, B ;

Mateo, G ;

Gutiérrez, N ;

Bladé, J ;

Schenkein, D ;

Pandiella, A ;

San Miguel, JF .

INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (04) :665-667

[6]

International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[7]

Hideshima T, 2001, CANCER RES, V61, P3071

[8]

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma [J].

Jagannath, S ;

Barlogie, B ;

Berenson, J ;

Siegel, D ;

Irwin, D ;

Richardson, PG ;

Niesvizky, R ;

Alexanian, R ;

Limentani, SA ;

Alsina, M ;

Adams, J ;

Kauffman, M ;

Esseltine, DL ;

Schenkein, DP ;

Anderson, KC .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (02) :165-172

[9]

Ma MH, 2003, CLIN CANCER RES, V9, P1136

[10]

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications [J].

Mitsiades, N ;

Mitsiades, CS ;

Richardson, PG ;

Poulaki, V ;

Tai, YT ;

Chauhan, D ;

Fanourakis, G ;

Gu, XS ;

Bailey, C ;

Joseph, M ;

Libermann, TA ;

Schlossman, R ;

Munshi, NC ;

Hideshima, T ;

Anderson, KC .

BLOOD, 2003, 101 (06) :2377-2380

← 1 2 →